Amgen Announces New Data At The American Heart Association Scientific Sessions 2026; New Late-Breaking Findings Show That Repatha Was A Highly Cost-Effective Treatment Option for High-Risk Patients Without A Prior Heart Attack Or Stroke

By Benzinga Newsdesk

Keep reading.

TUTORIALS

UBS Maintains Buy on Walmart, Raises Price Target to $149

TUTORIALS

Nvidia Is Now Nearly 3 Times Cheaper Than Intel on Forward Earnings

TUTORIALS

JP Morgan Maintains Overweight on Home Depot, Raises Price Target to $400

Trade what
you just read.

Apply the analysis on a live or demo account, same execution, no risk on demo.

Your seat at the market is ready.

Open your account in minutes, transparent pricing, fast withdrawals and support that answers.

Try a free demo

CFDs are complex instruments. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Amgen Announces New Data At The American Heart Association Scientific Sessions 2026; New Late-Breaking Findings Show That Repatha Was A Highly Cost-Effective Treatment Option for High-Risk Patients Without A Prior Heart Attack Or Stroke

Trade whatyou just read.

Your seat at the market is ready.

Trade what
you just read.